Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Bailey CJ, Tahrani AA, Barnett AH (2016) Future glucose-lowering drugs for type 2 diabetes
[PMID 38958939, PMID 39976940, PMID 42060879] CONTRAINDICATIONS A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy PRECAUTIONS Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Stomach disorders Wegovy slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like Wegovy, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures
Ready for a personal clinical session
PubMed Clinical Studies on Semaglutide Database di studi clinici e ricerche scientifiche sul semaglutide
US$ 24.71
US$ 22.09
US$ 28.81
US$ 27.79
US$ 21.58
